TMPRSS4 Antibody (D-1): sc-390875
- TMPRSS4 Antibody (D-1) is a mouse monoclonal IgG1 κ provided at 200 µg/ml
- raised against amino acids 295-370 mapping within an internal region of TMPRSS4 of human origin
- recommended for detection of TMPRSS4 of human origin by WB, IP, IF and ELISA
- m-IgG Fc BP-HRP and m-IgG1 BP-HRP are the preferred secondary detection reagents for TMPRSS4 Antibody (D-1) for WB applications. These reagents are now offered in bundles with TMPRSS4 Antibody (D-1) (see ordering information below).
QUICK LINKS
TMPRSS4 Antibody (D-1) is a mouse monoclonal IgG1 antibody that detects TMPRSS4 in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). TMPRSS4, also known as transmembrane protease, serine 4, is a single-pass type II membrane protein characterized by one SRCR domain, one LDL-receptor class A domain, and one peptidase S1 domain, which collectively contribute to enzymatic activity. TMPRSS4 is primarily localized to the cell surface, where anti-TMPRSS4 antibody (D-1) can detect its role in degrading extracellular matrix components, facilitating tumor cell invasion and metastasis. TMPRSS4 shows weak expression in normal tissues but exhibits significantly elevated levels in various cancers, including gastric, pancreatic, ampullary, and colorectal cancers, highlighting potential use as a biomarker for tumor progression. TMPRSS4′s ability to activate growth factors and promote angiogenesis further underscores importance in cancer biology, making TMPRSS4 monoclonal antibody (D-1) an essential tool for researchers investigating tumor dynamics and therapeutic targets.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
TMPRSS4 Antibody (D-1) References:
- Role of TMPRSS4 during cancer progression. | Choi, SY., et al. 2008. Drug News Perspect. 21: 417-23. PMID: 19034347
- Prognostic significance of TMPRSS4 in gastric cancer. | Sheng, H., et al. 2014. Neoplasma. 61: 213-7. PMID: 24299317
- Identification of potential transmembrane protease serine 4 inhibitors as anti-cancer agents by integrated computational approach. | Ilamathi, M., et al. 2016. J Theor Biol. 389: 253-62. PMID: 26590327
- TMPRSS4 as an emerging potential poor prognostic factor for solid tumors: A systematic review and meta-analysis. | Zeng, P., et al. 2016. Oncotarget. 7: 76327-76336. PMID: 27344186
- Transmembrane Protease TMPRSS4 Promotes the Formation and Development of Mismatch Repair Deficient Colon Cancer Liver Metastasis. | Yang, YS., et al. 2021. Bull Exp Biol Med. 171: 242-246. PMID: 34173918
- Utility of TMPRSS4 as a Prognostic Biomarker and Potential Therapeutic Target in Patients with Gastric Cancer. | Tazawa, H., et al. 2022. J Gastrointest Surg. 26: 305-313. PMID: 34379296
- Type II transmembrane serine proteases 4 (TMPRSS4) promotes proliferation, invasion and epithelial-mesenchymal transition in endometrial carcinoma cells (HEC1A and Ishikawa) via activation of MAPK and AKT. | Xiao, H., et al. 2021. Anim Cells Syst (Seoul). 25: 211-218. PMID: 34408809
- TMPRSS4 promotes cancer stem-like properties in prostate cancer cells through upregulation of SOX2 by SLUG and TWIST1. | Lee, Y., et al. 2021. J Exp Clin Cancer Res. 40: 372. PMID: 34809669
- Protein expression of transmembrane protease serine 4 in the gastrointestinal tract and in healthy, cancer, and SARS‑CoV‑2 infected lungs. | Kerslake, R., et al. 2022. Mol Med Rep. 25: PMID: 35211765
- TMPRSS4 is a novel biomarker and correlated with immune infiltration in thyroid carcinoma. | Xu, X., et al. 2022. BMC Endocr Disord. 22: 280. PMID: 36380313
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TMPRSS4 Antibody (D-1) | sc-390875 | 200 µg/ml | $322.00 | |||
TMPRSS4 Antibody (D-1): m-IgG Fc BP-HRP Bundle | sc-540866 | 200 µg Ab; 10 µg BP | $361.00 | |||
TMPRSS4 Antibody (D-1): m-IgG1 BP-HRP Bundle | sc-542428 | 200 µg Ab; 20 µg BP | $361.00 |